Fairmount Funds Management LLC: CRESCENT BIOPHARMA INC. (CBIO): Quarterly 13F Position History
As of Q1 2026, Fairmount Funds Management LLC reported 2,747,866 shares of CRESCENT BIOPHARMA INC. (CBIO), worth $50.5M and representing 3.6% of its 13F equity book. The position first appeared in Q2 2025 and has been disclosed across 4 13F-HR filings in Pactolio's tracked window.
- 2,747,866Shares Held (Latest Filing)
- $50.5MReported Market Value (Latest Filing)
- 3.6%Portfolio Weight (% of 13F Equity Book)
- 0Quarter-over-Quarter Share Change
- +$17.9MQuarter-over-Quarter Value Change
- 2,747,866Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 4 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q1 2026 | 2,747,866 | 0 | — | $50.5M | 3.6% | $18.4 |
| Q4 2025 | 2,747,866 | +1,360,000 | +98.0% | $32.6M | 2.5% | $11.9 |
| Q3 2025 | 1,387,866 | 0 | — | $16.5M | 1.5% | $11.9 |
| Q2 2025 | 1,387,866 | — | — | $22.4M | 2.9% | $16.1 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares — a quarter-end mark, not the manager's cost basis. See the full methodology document for the normalization rules.
When did Fairmount Funds Management LLC first disclose a CBIO position in 13F-HR filings?
Fairmount Funds Management LLC first reported CRESCENT BIOPHARMA INC. (CBIO) on its 13F-HR filing for the period ending 2025-06-30 (Q2 2025). The position has appeared on 4 reported quarters within Pactolio's tracked window.
What was Fairmount Funds Management LLC's most recent quarter-over-quarter share-count change in CBIO?
Fairmount Funds Management LLC held the same 2,747,866 shares of CBIO between Q4 2025 and Q1 2026 — the reported share count was unchanged quarter-over-quarter.
Does the implied price-per-share represent Fairmount Funds Management LLC's cost basis in CBIO?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.